These differences in chemotherapy regimens, the prevalence of EGFR/ALK mutations, and PD-L1 status highlight the need for further research in order to refine patient selection and better explain the long-term safety and efficacy of adjuvant ICIs in NSCLC [Table 1]. This evidence concerns the gene ALK and non-small cell lung carcinoma.